Endogenous Sex Hormones and Prostate Cancer Risk

A Case-Control Study Nested within the Carotene and Retinol Efficacy Trial

Chu Chen, Noel S. Weiss, Frank Z. Stanczyk, S. Kay Lewis, Dante DiTommaso, Ruth Etzioni, Matt J. Barnett, Gary E. Goodman

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

To examine whether endogenous androgens influence the occurrence of prostate cancer, we conducted a nested case-control study among participants enrolled in the Carotene and Retinol Efficacy Trial. We analyzed serum samples of 300 cases diagnosed between 1987 and 1998, and 300 matched controls. Higher concentrations of testosterone (T) were not associated with increased prostate cancer risk. Relative to men with levels in the lowest fourth of the distribution, men in the upper fourth of total T had a risk of 0.82 [95% confidence interval (CI), 0.52-1.29]. The corresponding relative risks for free T (0.72; 95% CI, 0.45-1.14), percentage of free T (0.74; 95% CI, 0.46-1.19), and total T:sex hormone binding globulin ratio (0.52; 95% CI, 0.32-0.83) similarly were not elevated. Higher concentrations of androstenedione, dehydroeplandrosterone sulfate, and 3α-androstanediol glucuronide were weakly associated with risk. Relative risks associated with being in the highest fourth for androstenedione, dehydroepiandrosterone sulfate, and 3α-androstanediol glucuronide were 1.20 (95% CI, 0.76-1.89), 1.38 (95% CI, 0.86-2.21), and 1.27 (95% CI, 0.80-2.00), respectively. Men in the upper fourth of total estradiol (E2), free E2 and percentage of free E2 had relative risks of 0.71 (95% CI, 0.42-1.13), 0.52 (95% CI, 0.33-0.82), and 0.65 (95% CI, 0.40-1.05), respectively. The inverse association between E2 and prostate cancer risk was largely restricted to men with blood collection within 3 years of diagnosis. Our results add to the evidence that serum testosterone is unrelated to prostate cancer incidence. The suggestions that intraprostatic androgen activity may increase risk and that serum estrogens may decrease risk, warrant additional study.

Original languageEnglish (US)
Pages (from-to)1410-1416
Number of pages7
JournalCancer Epidemiology Biomarkers and Prevention
Volume12
Issue number12
StatePublished - Dec 1 2003
Externally publishedYes

Fingerprint

Gonadal Steroid Hormones
Carotenoids
Vitamin A
Case-Control Studies
Prostatic Neoplasms
Confidence Intervals
Androstenedione
Glucuronides
Androgens
Testosterone
Serum
Sex Hormone-Binding Globulin
Dehydroepiandrosterone Sulfate
Sulfates
Estradiol
Estrogens
Incidence

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Chen, C., Weiss, N. S., Stanczyk, F. Z., Lewis, S. K., DiTommaso, D., Etzioni, R., ... Goodman, G. E. (2003). Endogenous Sex Hormones and Prostate Cancer Risk: A Case-Control Study Nested within the Carotene and Retinol Efficacy Trial. Cancer Epidemiology Biomarkers and Prevention, 12(12), 1410-1416.

Endogenous Sex Hormones and Prostate Cancer Risk : A Case-Control Study Nested within the Carotene and Retinol Efficacy Trial. / Chen, Chu; Weiss, Noel S.; Stanczyk, Frank Z.; Lewis, S. Kay; DiTommaso, Dante; Etzioni, Ruth; Barnett, Matt J.; Goodman, Gary E.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 12, No. 12, 01.12.2003, p. 1410-1416.

Research output: Contribution to journalArticle

Chen, C, Weiss, NS, Stanczyk, FZ, Lewis, SK, DiTommaso, D, Etzioni, R, Barnett, MJ & Goodman, GE 2003, 'Endogenous Sex Hormones and Prostate Cancer Risk: A Case-Control Study Nested within the Carotene and Retinol Efficacy Trial', Cancer Epidemiology Biomarkers and Prevention, vol. 12, no. 12, pp. 1410-1416.
Chen, Chu ; Weiss, Noel S. ; Stanczyk, Frank Z. ; Lewis, S. Kay ; DiTommaso, Dante ; Etzioni, Ruth ; Barnett, Matt J. ; Goodman, Gary E. / Endogenous Sex Hormones and Prostate Cancer Risk : A Case-Control Study Nested within the Carotene and Retinol Efficacy Trial. In: Cancer Epidemiology Biomarkers and Prevention. 2003 ; Vol. 12, No. 12. pp. 1410-1416.
@article{17ee5da3b39b4ec7b2ef7ef87f12549f,
title = "Endogenous Sex Hormones and Prostate Cancer Risk: A Case-Control Study Nested within the Carotene and Retinol Efficacy Trial",
abstract = "To examine whether endogenous androgens influence the occurrence of prostate cancer, we conducted a nested case-control study among participants enrolled in the Carotene and Retinol Efficacy Trial. We analyzed serum samples of 300 cases diagnosed between 1987 and 1998, and 300 matched controls. Higher concentrations of testosterone (T) were not associated with increased prostate cancer risk. Relative to men with levels in the lowest fourth of the distribution, men in the upper fourth of total T had a risk of 0.82 [95{\%} confidence interval (CI), 0.52-1.29]. The corresponding relative risks for free T (0.72; 95{\%} CI, 0.45-1.14), percentage of free T (0.74; 95{\%} CI, 0.46-1.19), and total T:sex hormone binding globulin ratio (0.52; 95{\%} CI, 0.32-0.83) similarly were not elevated. Higher concentrations of androstenedione, dehydroeplandrosterone sulfate, and 3α-androstanediol glucuronide were weakly associated with risk. Relative risks associated with being in the highest fourth for androstenedione, dehydroepiandrosterone sulfate, and 3α-androstanediol glucuronide were 1.20 (95{\%} CI, 0.76-1.89), 1.38 (95{\%} CI, 0.86-2.21), and 1.27 (95{\%} CI, 0.80-2.00), respectively. Men in the upper fourth of total estradiol (E2), free E2 and percentage of free E2 had relative risks of 0.71 (95{\%} CI, 0.42-1.13), 0.52 (95{\%} CI, 0.33-0.82), and 0.65 (95{\%} CI, 0.40-1.05), respectively. The inverse association between E2 and prostate cancer risk was largely restricted to men with blood collection within 3 years of diagnosis. Our results add to the evidence that serum testosterone is unrelated to prostate cancer incidence. The suggestions that intraprostatic androgen activity may increase risk and that serum estrogens may decrease risk, warrant additional study.",
author = "Chu Chen and Weiss, {Noel S.} and Stanczyk, {Frank Z.} and Lewis, {S. Kay} and Dante DiTommaso and Ruth Etzioni and Barnett, {Matt J.} and Goodman, {Gary E.}",
year = "2003",
month = "12",
day = "1",
language = "English (US)",
volume = "12",
pages = "1410--1416",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Endogenous Sex Hormones and Prostate Cancer Risk

T2 - A Case-Control Study Nested within the Carotene and Retinol Efficacy Trial

AU - Chen, Chu

AU - Weiss, Noel S.

AU - Stanczyk, Frank Z.

AU - Lewis, S. Kay

AU - DiTommaso, Dante

AU - Etzioni, Ruth

AU - Barnett, Matt J.

AU - Goodman, Gary E.

PY - 2003/12/1

Y1 - 2003/12/1

N2 - To examine whether endogenous androgens influence the occurrence of prostate cancer, we conducted a nested case-control study among participants enrolled in the Carotene and Retinol Efficacy Trial. We analyzed serum samples of 300 cases diagnosed between 1987 and 1998, and 300 matched controls. Higher concentrations of testosterone (T) were not associated with increased prostate cancer risk. Relative to men with levels in the lowest fourth of the distribution, men in the upper fourth of total T had a risk of 0.82 [95% confidence interval (CI), 0.52-1.29]. The corresponding relative risks for free T (0.72; 95% CI, 0.45-1.14), percentage of free T (0.74; 95% CI, 0.46-1.19), and total T:sex hormone binding globulin ratio (0.52; 95% CI, 0.32-0.83) similarly were not elevated. Higher concentrations of androstenedione, dehydroeplandrosterone sulfate, and 3α-androstanediol glucuronide were weakly associated with risk. Relative risks associated with being in the highest fourth for androstenedione, dehydroepiandrosterone sulfate, and 3α-androstanediol glucuronide were 1.20 (95% CI, 0.76-1.89), 1.38 (95% CI, 0.86-2.21), and 1.27 (95% CI, 0.80-2.00), respectively. Men in the upper fourth of total estradiol (E2), free E2 and percentage of free E2 had relative risks of 0.71 (95% CI, 0.42-1.13), 0.52 (95% CI, 0.33-0.82), and 0.65 (95% CI, 0.40-1.05), respectively. The inverse association between E2 and prostate cancer risk was largely restricted to men with blood collection within 3 years of diagnosis. Our results add to the evidence that serum testosterone is unrelated to prostate cancer incidence. The suggestions that intraprostatic androgen activity may increase risk and that serum estrogens may decrease risk, warrant additional study.

AB - To examine whether endogenous androgens influence the occurrence of prostate cancer, we conducted a nested case-control study among participants enrolled in the Carotene and Retinol Efficacy Trial. We analyzed serum samples of 300 cases diagnosed between 1987 and 1998, and 300 matched controls. Higher concentrations of testosterone (T) were not associated with increased prostate cancer risk. Relative to men with levels in the lowest fourth of the distribution, men in the upper fourth of total T had a risk of 0.82 [95% confidence interval (CI), 0.52-1.29]. The corresponding relative risks for free T (0.72; 95% CI, 0.45-1.14), percentage of free T (0.74; 95% CI, 0.46-1.19), and total T:sex hormone binding globulin ratio (0.52; 95% CI, 0.32-0.83) similarly were not elevated. Higher concentrations of androstenedione, dehydroeplandrosterone sulfate, and 3α-androstanediol glucuronide were weakly associated with risk. Relative risks associated with being in the highest fourth for androstenedione, dehydroepiandrosterone sulfate, and 3α-androstanediol glucuronide were 1.20 (95% CI, 0.76-1.89), 1.38 (95% CI, 0.86-2.21), and 1.27 (95% CI, 0.80-2.00), respectively. Men in the upper fourth of total estradiol (E2), free E2 and percentage of free E2 had relative risks of 0.71 (95% CI, 0.42-1.13), 0.52 (95% CI, 0.33-0.82), and 0.65 (95% CI, 0.40-1.05), respectively. The inverse association between E2 and prostate cancer risk was largely restricted to men with blood collection within 3 years of diagnosis. Our results add to the evidence that serum testosterone is unrelated to prostate cancer incidence. The suggestions that intraprostatic androgen activity may increase risk and that serum estrogens may decrease risk, warrant additional study.

UR - http://www.scopus.com/inward/record.url?scp=0347993724&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347993724&partnerID=8YFLogxK

M3 - Article

VL - 12

SP - 1410

EP - 1416

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 12

ER -